other material
confidence high
sentiment positive
materiality 0.85
Setrusumab Phase 2 data: 67% fracture rate reduction in OI at 14 months
Mereo BioPharma Group plc
- Median annualized fracture rate reduced 67% to 0.00 (p=0.0014, n=24) vs pre-treatment 0.72.
- Lumbar spine BMD increased mean 22% at 12 months (p<0.0001, n=19); Z-score improved +1.25 (p<0.0001, n=18).
- No treatment-related serious adverse events or hypersensitivity reactions reported.
- Phase 3 Orbit (158 patients) and Cosmic (69 patients) studies fully enrolled.